AngioDynamics (ANGO) Projected to Release Earnings on Thursday

Key Points

• AngioDynamics is expected to report Q1 fiscal 2027 results before market open on October 1, 2026. Analysts project a loss of $0.1125 per share and revenue of $80.51 million; full-year guidance is for an EPS loss of $0.24–$0.29.
• The company’s latest quarter exceeded expectations, with EPS of negative $0.07 versus the estimated negative $0.11 and revenue of $86.61 million versus the $80.24 million consensus. However, AngioDynamics remains unprofitable, with an 11.48% negative net margin.
• Analyst sentiment is mixed: the consensus rating is “Hold” with a $19.50 price target, while some firms raised targets and issued “Buy” ratings and others downgraded the stock to “Sell” or “Strong Sell.” Shares opened at $15.51, near their 12-month high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) will likely be announcing its Q1 2027 results before the market opens on Thursday, October 1st. Analysts expect AngioDynamics to announce earnings of ($0.1125) per share and revenue of $80.51 million for the quarter. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Individuals may visit the the company's upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, October 1, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. On average, analysts expect AngioDynamics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

AngioDynamics Stock Down 1.0%

ANGO opened at $15.51 on Thursday. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The company has a fifty day moving average of $15.21 and a 200-day moving average of $12.80. The stock has a market cap of $641.03 million, a PE ratio of -17.83 and a beta of 0.33.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the firm's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company's stock, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 6.00% of the company's stock.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of recent analyst reports. HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Canaccord Genuity Group raised their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Finally, Zacks Research downgraded AngioDynamics from a "hold" rating to a "strong sell" rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, AngioDynamics currently has an average rating of "Hold" and a consensus price target of $19.50.

AngioDynamics Company Profile

AngioDynamics, Inc NASDAQ: ANGO is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company's product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.